Live Typhoid and Yellow Fever Vaccines Administered to a Patient With Ulcerative Colitis on Vedolizumab.

Patients with inflammatory bowel disease who receive immunosuppressive therapy have an increased risk of infection. Live vaccines are contraindicated in these patients because of the increased risk of unchecked replication of the attenuated vaccine microorganisms. Vedolizumab is a gut-selective biological agent with a low risk of infection approved for the treatment of inflammatory bowel disease. There are limited data on the risk of providing a live vaccine in patients receiving vedolizumab, and patients may receive live vaccines if the benefits outweigh the risks. We describe a patient with ulcerative colitis, treated with vedolizumab who received 2 live vaccines, typhoid and yellow fever, without postimmunization adverse events.